908
Views
2
CrossRef citations to date
0
Altmetric
Research Paper

Suppression of bone remodeling associated with long-term bisphosphonate treatment is mediated by microRNA-30a-5p

, , &
Pages 9741-9753 | Received 13 Jan 2022, Accepted 09 Mar 2022, Published online: 12 Apr 2022

References

  • Eriksen EF, Diez-Perez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone. 2014;58:126–135.
  • Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American society for bone and mineral research. J Bone Miner Res. 2016;31(10):1910.
  • North American Menopause, S. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause. 2006;13(3):340–67; quiz 368–9.
  • Marcus R. Post-menopausal osteoporosis. Best Pract Res Clin Obstet Gynaecol. 2002;16(3):309–327.
  • Khosla S, Melton LJ 3rd, Riggs BL. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res. 2011;26(3):441–451.
  • Kalyanaraman H, Ramdani G, Joshua J, et al. A novel, direct NO donor regulates osteoblast and osteoclast functions and increases bone mass in ovariectomized mice. J Bone Miner Res. 2017;32(1):46–59.
  • Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377(9773):1276–1287.
  • Zhao R, Zhao M, Xu Z. The effects of differing resistance training modes on the preservation of bone mineral density in postmenopausal women: a meta-analysis. Osteoporos Int. 2015;26(5):1605–1618.
  • Ghirardi A, Scotti L, Zambon A, et al. Risk of severe upper gastrointestinal complications among oral bisphosphonate users. PLoS One. 2013;8(12):e73159.
  • Ott SM. Bisphosphonate safety and efficacy in chronic kidney disease. Kidney Int. 2012;82(8):833–835.
  • Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society for bone and mineral research. J Bone Miner Res. 2007;22(10):1479–1491.
  • Bauer DC, Abrahamsen B. Bisphosphonate drug holidays in primary care: when and what to do next? Curr Osteoporos Rep. 2021;19(2):182–188.
  • Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc. 2009;84(7):632–637. quiz 638.
  • He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522–531.
  • Wang X, Guo B, Li Q, et al. miR-214 targets ATF4 to inhibit bone formation. Nat Med. 2013;19(1):93–100.
  • Wang Q, Miao Y, Qian Z, et al. MicroRNA-15a-5p plays a role in osteogenic MC3T3-E1 cells differentiation by targeting PDCD4 (programmed cell death 4) via Wnt/beta-catenin dependent signaling pathway. Bioengineered. 2021;12(1):8173–8185.
  • Gu H, Shi S, Xiao F, et al. MiR-1-3p regulates the differentiation of mesenchymal stem cells to prevent osteoporosis by targeting secreted frizzled-related protein 1. Bone. 2020;137:115444.
  • Li D, Liu J, Guo B, et al. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat Commun. 2016;7:10872 .
  • Asano N, Matsuzaki J, Ichikawa M, et al. A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes. Nat Commun. 2019;10(1):1299.
  • Panach L, Mifsut D, Tarin JJ, et al. Serum circulating MicroRNAs as biomarkers of osteoporotic fracture. Calcif Tissue Int. 2015;97(5):495–505.
  • Luo Y, Zhang Y, Miao G, et al. Runx1 regulates osteogenic differentiation of BMSCs by inhibiting adipogenesis through Wnt/beta-catenin pathway. Arch Oral Biol. 2019;97:176–184.
  • Liu Y, Wang H, Zhou XZ, et al. Pentraxin 3 promotes the osteoblastic differentiation of MC3T3-E1 cells through the PI3K/Akt signaling pathway. Biosci Rep. 2020;40(6):BSR20201165.
  • Yuan FL, Xu RS, Jiang DL, et al. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-kappaB and PI3K/Akt signaling pathways. Bone. 2015;75:128–137.
  • Bellavia D, De Luca A, Carina V, et al. Deregulated miRNAs in bone health: epigenetic roles in osteoporosis. Bone. 2019;122:52–75.
  • Wang H, Shi X, Guo Z, et al. microRNA-211-5p predicts the progression of postmenopausal osteoporosis and attenuates osteogenesis by targeting dual specific phosphatase 6. Bioengineered. 2022;13(3):5709–5723.
  • Huang J, Chen D. miRNAs in circulation: mirroring bone conditions? J Bone Miner Res. 2014;29(8):1715–1717.
  • de Bruijn M, Dzierzak E. Runx transcription factors in the development and function of the definitive hematopoietic system. Blood. 2017;129(15):2061–2069.
  • Ji C, Liu X, Xu L, et al. RUNX1 plays an important role in mediating BMP9-induced osteogenic differentiation of mesenchymal Stem Cells Line C3H10T1/2, Murine Multi-Lineage Cells Lines C2C12 and MEFs. Int J Mol Sci. 2017;18(7):1348.